-
1
-
-
49249119415
-
A synthetic lethal therapeutic approach: Poly (ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair
-
Ashworth A (2008). A synthetic lethal therapeutic approach: Poly (ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol, 26, 3785-90.
-
(2008)
J Clin Oncol
, vol.26
, pp. 3785-3790
-
-
Ashworth, A.1
-
2
-
-
82955187346
-
Breast cancer subtypes and outcomes of central nervous system metastases
-
Arslan UY, Oksuzoglu B, Aksoy S, et al (2011). Breast cancer subtypes and outcomes of central nervous system metastases. Breast, 20, 562-7.
-
(2011)
Breast
, vol.20
, pp. 562-567
-
-
Arslan, U.Y.1
Oksuzoglu, B.2
Aksoy, S.3
-
3
-
-
0038010542
-
Central nervous system metastases in women receive trastuzumabbased therapy for metastatic breast carcinoma
-
Bendell JC, Domchek SM, Burstein HJ, et al (2003). Central nervous system metastases in women receive trastuzumabbased therapy for metastatic breast carcinoma. Cancer, 97, 2972-7.
-
(2003)
Cancer
, vol.97
, pp. 2972-2977
-
-
Bendell, J.C.1
Domchek, S.M.2
Burstein, H.J.3
-
4
-
-
0030200669
-
Central nervous system metastasis in breast cancer
-
Boogerd W (1996). Central nervous system metastasis in breast cancer. Radiother Oncol, 40, 5-22.
-
(1996)
Radiother Oncol
, vol.40
, pp. 5-22
-
-
Boogerd, W.1
-
5
-
-
0033670117
-
Single-agent gemcitabine as second-and third-line treatment in metastatic breast cancer
-
Brodowicz T, Kostler WJ, Moslinger R, et al (2000). Single-agent gemcitabine as second-and third-line treatment in metastatic breast cancer. Breast, 9, 338-42.
-
(2000)
Breast
, vol.9
, pp. 338-342
-
-
Brodowicz, T.1
Kostler, W.J.2
Moslinger, R.3
-
6
-
-
67349284098
-
Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
-
Byrski T, Huzarski T, Dent R, et al (2009). Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat, 115, 359-63.
-
(2009)
Breast Cancer Res Treat
, vol.115
, pp. 359-363
-
-
Byrski, T.1
Huzarski, T.2
Dent, R.3
-
7
-
-
77957118417
-
Cancer staging manual AJCC
-
Seventh Edition, Springer, Chicago
-
Cancer staging manual AJCC (2010) Seventh Edition, Springer, Chicago.
-
(2010)
-
-
-
8
-
-
12344330438
-
Central nervous system metastases in women after multimodality therapy for high risk breast cancer
-
Carey LA, Ewend MG, Metzger R, et al (2004). Central nervous system metastases in women after multimodality therapy for high risk breast cancer. Breast Cancer Res Treat, 88, 273-80.
-
(2004)
Breast Cancer Res Treat
, vol.88
, pp. 273-280
-
-
Carey, L.A.1
Ewend, M.G.2
Metzger, R.3
-
9
-
-
0028799915
-
Advanced breast cancer: a phase II trial with gemcitabine
-
Carmichael J, Possinger K, Philip P, et al (1995). Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol, 13, 2731-6.
-
(1995)
J Clin Oncol
, vol.13
, pp. 2731-2736
-
-
Carmichael, J.1
Possinger, K.2
Philip, P.3
-
10
-
-
0018630244
-
The natural history of breast cancer patients with brain metastases
-
DiStefano A, Yong YY, Hortobagyi GN, Blumenschein GR (1979). The natural history of breast cancer patients with brain metastases. Cancer, 44, 1913-8.
-
(1979)
Cancer
, vol.44
, pp. 1913-1918
-
-
DiStefano, A.1
Yong, Y.Y.2
Hortobagyi, G.N.3
Blumenschein, G.R.4
-
11
-
-
0010607397
-
Significant activity of gemcitabine (Gem) and cisplatin (Ddp) in both heavily (H) and minimally (M)-pretreated metastatic breast cancer (Mbc) patients (Pts): a california cancer consortium/ loyola Univ Chicago Trial (Abstract)
-
Doroshow J, Tetef M, Margolin K, et al (2000). Significant activity of gemcitabine (Gem) and cisplatin (Ddp) in both heavily (H) and minimally (M)-pretreated metastatic breast cancer (Mbc) patients (Pts): a california cancer consortium/ loyola Univ Chicago Trial (Abstract). Proc Am Soc Clin Oncol, 19, 609.
-
(2000)
Proc Am Soc Clin Oncol
, vol.19
, pp. 609
-
-
Doroshow, J.1
Tetef, M.2
Margolin, K.3
-
12
-
-
52049083921
-
Survival in patients with brain metastases from breast cancer: the importance of HER-2 status
-
Eichler AF, Kuter I, Ryan P, et al (2008). Survival in patients with brain metastases from breast cancer: the importance of HER-2 status. Cancer, 112, 2359-67.
-
(2008)
Cancer
, vol.112
, pp. 2359-2367
-
-
Eichler, A.F.1
Kuter, I.2
Ryan, P.3
-
14
-
-
0020320349
-
Cisplatin in the treatment of metastatic breast carcinoma: A prospective randomized trial of two dosage schedules
-
Forastiere AA, Hakes TB, Wittes JT, Wittes RE (1982). Cisplatin in the treatment of metastatic breast carcinoma: A prospective randomized trial of two dosage schedules. Am J Clin Oncol, 5, 243-7.
-
(1982)
Am J Clin Oncol
, vol.5
, pp. 243-247
-
-
Forastiere, A.A.1
Hakes, T.B.2
Wittes, J.T.3
Wittes, R.E.4
-
15
-
-
0009941731
-
Prognostic factors in breast cancer
-
Fitzgibbons PL, Page DL, Weaver D, et al (2000). Prognostic factors in breast cancer. College of American pathologists consensus statement 1999. Arch Pathol Lab Med, 124, 966-78.
-
(2000)
College of American pathologists consensus statement 1999. Arch Pathol Lab Med
, vol.124
, pp. 966-978
-
-
Fitzgibbons, P.L.1
Page, D.L.2
Weaver, D.3
-
16
-
-
34247346051
-
Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer
-
Gabos Z, Sinha R, Hanson J, et al (2006). Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol, 24, 5638-63.
-
(2006)
J Clin Oncol
, vol.24
, pp. 5638-5663
-
-
Gabos, Z.1
Sinha, R.2
Hanson, J.3
-
17
-
-
0002212883
-
Monthly cisplatin (C) and gemcitabine (G) as second line chemotherapy for patients with advanced breast cancer (Abstract)
-
Galvez CA, Calmarini F, Curie M (2000). Monthly cisplatin (C) and gemcitabine (G) as second line chemotherapy for patients with advanced breast cancer (Abstract). Breast Cancer Res Treat, 64, 81.
-
(2000)
Breast Cancer Res Treat
, vol.64
, pp. 81
-
-
Galvez, C.A.1
Calmarini, F.2
Curie, M.3
-
18
-
-
84882689733
-
Gemcitabine plus cisplatin in patients with heavily pretreated advanced breast cancer with brain metastases
-
Gorbunova VA, Bychkov MB, Naskhletashvili DR, et al (2010). Gemcitabine plus cisplatin in patients with heavily pretreated advanced breast cancer with brain metastases. J Clin Oncol, 28, 15.
-
(2010)
J Clin Oncol
, vol.28
, pp. 15
-
-
Gorbunova, V.A.1
Bychkov, M.B.2
Naskhletashvili, D.R.3
-
19
-
-
0036072839
-
Gemcitabine plus cisplatin for the treatment of metastatic breast cancer
-
Heinemann V (2002). Gemcitabine plus cisplatin for the treatment of metastatic breast cancer. Clin Breast Cancer, 3, 24-9.
-
(2002)
Clin Breast Cancer
, vol.3
, pp. 24-29
-
-
Heinemann, V.1
-
20
-
-
32544450815
-
High efficacy of gemcitabine and cisplatin in patients with predominantly anthracycline-and taxane-pretreated metastatic breast cancer
-
Heinemann V, Stemmler HJ, Wohlrab A, et al (2006). High efficacy of gemcitabine and cisplatin in patients with predominantly anthracycline-and taxane-pretreated metastatic breast cancer. Cancer Chemother Pharmacol, 57, 640-6.
-
(2006)
Cancer Chemother Pharmacol
, vol.57
, pp. 640-646
-
-
Heinemann, V.1
Stemmler, H.J.2
Wohlrab, A.3
-
21
-
-
0032521537
-
BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II)
-
Husain A, He G, Venkatraman ES, Spriggs DR (1998). BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res, 58, 1120-3.
-
(1998)
Cancer Res
, vol.58
, pp. 1120-1123
-
-
Husain, A.1
He, G.2
Venkatraman, E.S.3
Spriggs, D.R.4
-
22
-
-
82955235724
-
Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment
-
Kim H-J, Im S-A, Keam B, et al (2012). Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment. J Neurooncol, 106, 303-13.
-
(2012)
J Neurooncol
, vol.106
, pp. 303-313
-
-
Kim, H.-J.1
Im, S.-A.2
Keam, B.3
-
23
-
-
15744372470
-
Survival after brain metastases from breast cancer in the trastuzumab era
-
Kirsch DG, Ledezma CJ, Mathews CS, et al (2005). Survival after brain metastases from breast cancer in the trastuzumab era. J Clin Oncol, 23, 2114-6.
-
(2005)
J Clin Oncol
, vol.23
, pp. 2114-2116
-
-
Kirsch, D.G.1
Ledezma, C.J.2
Mathews, C.S.3
-
24
-
-
0020635273
-
Phase II clinical trial of cisdichlorodiammine platinum (cis-DDP) for antitumorigenic activity in previously untreated patients with metastatic breast cancer
-
Kolaric K, Roth A (1983). Phase II clinical trial of cisdichlorodiammine platinum (cis-DDP) for antitumorigenic activity in previously untreated patients with metastatic breast cancer. Cancer Chemother Pharmacol, 11, 108-12.
-
(1983)
Cancer Chemother Pharmacol
, vol.11
, pp. 108-112
-
-
Kolaric, K.1
Roth, A.2
-
25
-
-
51649114000
-
Brain metastases in breast cancer: prognostic factors and management
-
Lee SS, Ahn J-H, Kim MK, et al (2008). Brain metastases in breast cancer: prognostic factors and management. Breast Cancer Res Treat, 111, 523-30.
-
(2008)
Breast Cancer Res Treat
, vol.111
, pp. 523-530
-
-
Lee, S.S.1
Ahn, J.-H.2
Kim, M.K.3
-
26
-
-
34248166978
-
The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers
-
Leong CO, Vidnovic N, DeYoung MP, Sgroi D, Ellisen LW (2007). The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. J Clin Invest, 117, 1370-80.
-
(2007)
J Clin Invest
, vol.117
, pp. 1370-1380
-
-
Leong, C.O.1
Vidnovic, N.2
DeYoung, M.P.3
Sgroi, D.4
Ellisen, L.W.5
-
27
-
-
0034040110
-
Patterns of disease spread in metastatic breast carcinoma: influence of estrogen and progesterone receptor status
-
Maki DD, Grossman RI (2000). Patterns of disease spread in metastatic breast carcinoma: influence of estrogen and progesterone receptor status. Am J Neuroradiol, 21, 1064-6.
-
(2000)
Am J Neuroradiol
, vol.21
, pp. 1064-1066
-
-
Maki, D.D.1
Grossman, R.I.2
-
28
-
-
0019365237
-
Reporting results of cancer treatment
-
Miller AB, Hoogstraten B, Staquet M, Winkler A (1981). Reporting results of cancer treatment. Cancer, 47, 207-14.
-
(1981)
Cancer
, vol.47
, pp. 207-214
-
-
Miller, A.B.1
Hoogstraten, B.2
Staquet, M.3
Winkler, A.4
-
29
-
-
44849117865
-
Breast cancer subtypes and survival in patients with brain metastases
-
Nam BH, Kim SY, Han HS, et al (2008). Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res, 10, 20.
-
(2008)
Breast Cancer Res
, vol.10
, pp. 20
-
-
Nam, B.H.1
Kim, S.Y.2
Han, H.S.3
-
30
-
-
0034082923
-
Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients
-
Nagourney RA, Link JS, Blitzer JB, Forsthoff C, Evans SS (2000). Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients. J Clin Oncol, 18, 2245-9.
-
(2000)
J Clin Oncol
, vol.18
, pp. 2245-2249
-
-
Nagourney, R.A.1
Link, J.S.2
Blitzer, J.B.3
Forsthoff, C.4
Evans, S.S.5
-
31
-
-
77953346211
-
Breast cancer brain metastasis: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole brain radiotherapy (WBRT)
-
Niwinska A, Murawska M, Pogoda K (2010). Breast cancer brain metastasis: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole brain radiotherapy (WBRT). Ann Oncol, 21, 942-8.
-
(2010)
Ann Oncol
, vol.21
, pp. 942-948
-
-
Niwinska, A.1
Murawska, M.2
Pogoda, K.3
-
32
-
-
77957346508
-
Breast cancer subtypes and response to systemic treatment after wholebrain radiotherapy in patients with brain metastases
-
Niwinska A, Murawska M, Pogoda K (2010). Breast cancer subtypes and response to systemic treatment after wholebrain radiotherapy in patients with brain metastases. Cancer, 116, 4238-47.
-
(2010)
Cancer
, vol.116
, pp. 4238-4247
-
-
Niwinska, A.1
Murawska, M.2
Pogoda, K.3
-
33
-
-
0020396015
-
Toxicity and response criteria of the eastern cooperative oncology group
-
Oken MM, Creech RH, Tormey DC, et al (1982). Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol, 5, 649-55.
-
(1982)
Am J Clin Oncol
, vol.5
, pp. 649-655
-
-
Oken, M.M.1
Creech, R.H.2
Tormey, D.C.3
-
34
-
-
0018933559
-
High-dose cis-diamminedichloro-platinum therapy in patients with advanced breast cancer: pharmacokinetics, toxicity, and therapeutic efficacy
-
Ostrow S, Egorin M, Aisner J, Bchur N, Wiernik PH (1980). High-dose cis-diamminedichloro-platinum therapy in patients with advanced breast cancer: pharmacokinetics, toxicity, and therapeutic efficacy. Cancer Clin Trials, 3, 23-7.
-
(1980)
Cancer Clin Trials
, vol.3
, pp. 23-27
-
-
Ostrow, S.1
Egorin, M.2
Aisner, J.3
Bchur, N.4
Wiernik, P.H.5
-
35
-
-
58849137898
-
Prognostic factor analysis in patients with brain metastases from breast cancer: how can we improve the treatment outcomes
-
Park B-B, Uhm JE, Cho EY, et al (2009). Prognostic factor analysis in patients with brain metastases from breast cancer: how can we improve the treatment outcomes. Cancer Chemother Pharmacol, 63, 627-33.
-
(2009)
Cancer Chemother Pharmacol
, vol.63
, pp. 627-633
-
-
Park, B.-B.1
Uhm, J.E.2
Cho, E.Y.3
-
36
-
-
21244481753
-
Predictors of central nervous system metastasis in patients with metastatic breast cancer
-
Ryberg M, Nielsen D, Osterlind K, et al (2005). Predictors of central nervous system metastasis in patients with metastatic breast cancer. A competing risk analysis of 579 patients treated with epirubicin-based chemotherapy. Breast Cancer Res Treat, 91, 217-25.
-
(2005)
A competing risk analysis of 579 patients treated with epirubicin-based chemotherapy. Breast Cancer Res Treat
, vol.91
, pp. 217-225
-
-
Ryberg, M.1
Nielsen, D.2
Osterlind, K.3
-
37
-
-
0019378968
-
Estrogen receptor: a prognostic factor in breast cancer
-
Samaan NA, Buzdar AU, Aldinger KA, et al (1981). Estrogen receptor: a prognostic factor in breast cancer. Cancer (Phila), 47, 554-60.
-
(1981)
Cancer (Phila)
, vol.47
, pp. 554-560
-
-
Samaan, N.A.1
Buzdar, A.U.2
Aldinger, K.A.3
-
38
-
-
0032542216
-
A targeted disruption of the murine brca1 gene causes gamma-irradiation hypersensitivity and genetic instability
-
Shen SX, Weaver Z, Xu X, et al (1998). A targeted disruption of the murine brca1 gene causes gamma-irradiation hypersensitivity and genetic instability. Oncogene, 17, 3115-24.
-
(1998)
Oncogene
, vol.17
, pp. 3115-3124
-
-
Shen, S.X.1
Weaver, Z.2
Xu, X.3
-
40
-
-
65449152268
-
Cisplatin plus gemcitabine chemotherapy in taxane/anthracycline-resistant metastatic breast cancer
-
Somali I, Alacacioglu A, Tarhan MO, et al (2009). Cisplatin plus gemcitabine chemotherapy in taxane/anthracycline-resistant metastatic breast cancer. Chemotherapy, 55, 155-60.
-
(2009)
Chemotherapy
, vol.55
, pp. 155-160
-
-
Somali, I.1
Alacacioglu, A.2
Tarhan, M.O.3
-
41
-
-
17844373250
-
Singleagent gemcitabine is active in previously treated metastatic breast cancer
-
Spielmann M, Llombart-Cussac A, Kalla S, et al (2001). Singleagent gemcitabine is active in previously treated metastatic breast cancer. Oncology, 60, 303-7.
-
(2001)
Oncology
, vol.60
, pp. 303-307
-
-
Spielmann, M.1
Llombart-Cussac, A.2
Kalla, S.3
-
42
-
-
0021050124
-
Central nervous system metastasis from breast carcinoma
-
Tsukada Y, Fouad A, Pickren JW, Lane WW (1983). Central nervous system metastasis from breast carcinoma. Autopsy study. Cancer (Phila), 52, 2349-54.
-
(1983)
Autopsy study. Cancer (Phila)
, vol.52
, pp. 2349-2354
-
-
Tsukada, Y.1
Fouad, A.2
Pickren, J.W.3
Lane, W.W.4
-
43
-
-
60549106251
-
Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy
-
Uhm JE, Park YH, Yi SY, et al (2009). Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy. Int J Cancer, 124, 1457-62.
-
(2009)
Int J Cancer
, vol.124
, pp. 1457-1462
-
-
Uhm, J.E.1
Park, Y.H.2
Yi, S.Y.3
-
44
-
-
84863982081
-
Molecular insights on basal-like breast cancer
-
Valentin MD, Da Silva SD, Privat M, Alaoui-Jamali M, Bignon YJ (2012). Molecular insights on basal-like breast cancer. Breast Cancer Res Treat, 134, 21-30.
-
(2012)
Breast Cancer Res Treat
, vol.134
, pp. 21-30
-
-
Valentin, M.D.1
Da Silva, S.D.2
Privat, M.3
Alaoui-Jamali, M.4
Bignon, Y.J.5
-
45
-
-
0000979221
-
Gemcitabine (G) in pretreated breast cancer (BC)
-
Valerio M, Cicero G, Armata M, et al (2001). Gemcitabine (G) in pretreated breast cancer (BC). Proc Am Soc Clin Oncol, 20, 1953.
-
(2001)
Proc Am Soc Clin Oncol
, vol.20
, pp. 1953
-
-
Valerio, M.1
Cicero, G.2
Armata, M.3
-
46
-
-
84908844821
-
World Health Organization: WHO handbook for reporting results of cancer treatment
-
Geneva, Switzerland
-
World Health Organization: WHO handbook for reporting results of cancer treatment (1979) WHO Offset Publication, No. 48, Geneva, Switzerland.
-
(1979)
WHO Offset Publication
, Issue.48
-
-
|